000128930 001__ 128930
000128930 005__ 20240228143358.0
000128930 0247_ $$2doi$$a10.1007/s00280-016-3023-9
000128930 0247_ $$2WOS$$aWOS:000376985500021
000128930 0247_ $$2ISSN$$a0344-5704
000128930 0247_ $$2ISSN$$a0943-9404
000128930 0247_ $$2ISSN$$a1432-0843
000128930 0247_ $$2altmetric$$aaltmetric:6829251
000128930 0247_ $$2pmid$$apmid:27094900
000128930 037__ $$aDKFZ-2017-04942
000128930 082__ $$a610
000128930 1001_ $$aKönig, Miriam$$b0
000128930 245__ $$aErratum to: Investigation of ototoxicity of artesunate as add-on therapy in patients with metastatic or locally advanced breast cancer: new audiological results from a prospective, open, uncontrolled, monocentric phase I study
000128930 260__ $$aBerlin$$bSpringer62507$$c2016
000128930 3367_ $$2DRIVER$$aarticle
000128930 3367_ $$2DataCite$$aOutput Types/Journal article
000128930 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1531141192_16864$$xErratum/Correction
000128930 3367_ $$2BibTeX$$aARTICLE
000128930 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128930 3367_ $$00$$2EndNote$$aJournal Article
000128930 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000128930 542__ $$2Crossref$$i2016-04-19$$uhttp://www.springer.com/tdm
000128930 588__ $$aDataset connected to Web of Science, Web of Science, , CrossRef
000128930 7001_ $$avon Hagens, Cornelia$$b1
000128930 7001_ $$aHoth, Sebastian$$b2
000128930 7001_ $$aBaumann, Ingo$$b3
000128930 7001_ $$aWalter-Sack, Ingeborg$$b4
000128930 7001_ $$0P:(DE-He78)621efe295db6fdfa7f9f95011a5ea943$$aEdler, Lutz$$b5$$udkfz
000128930 7001_ $$aSertel, Serkan$$b6
000128930 77318 $$2Crossref$$3journal-article$$a10.1007/s00280-016-3023-9$$bSpringer Science and Business Media LLC$$d2016-04-19$$n6$$p1321-1321$$tCancer Chemotherapy and Pharmacology$$v77$$x0344-5704$$y2016
000128930 773__ $$0PERI:(DE-600)1458488-8$$a10.1007/s00280-016-3023-9$$gVol. 77, no. 6, p. 1321 - 1321$$n6$$p1321-1321$$tCancer chemotherapy and pharmacology$$v77$$x0344-5704$$y2016
000128930 909CO $$ooai:inrepo02.dkfz.de:128930$$pVDB
000128930 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)621efe295db6fdfa7f9f95011a5ea943$$aDeutsches Krebsforschungszentrum$$b5$$kDKFZ
000128930 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000128930 9141_ $$y2016
000128930 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128930 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000128930 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000128930 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128930 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128930 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bCANCER CHEMOTH PHARM : 2015
000128930 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128930 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000128930 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128930 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128930 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000128930 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000128930 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128930 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000128930 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x0
000128930 980__ $$ajournal
000128930 980__ $$aVDB
000128930 980__ $$aI:(DE-He78)C060-20160331
000128930 980__ $$aUNRESTRICTED